• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
CDO Spotlight: CLO Tranche Recovery Metrics Update: June 2011 Jun 11 Product Image

CDO Spotlight: CLO Tranche Recovery Metrics Update: June 2011 Jun 11

  • ID: 1829601
  • June 2011
  • Standard & Poors


  • 1776 CLO I Ltd
  • Canaras Summit CLO Ltd
  • HarbourView CLO 2006-1
  • LightPoint CLO VII, Ltd.
  • Rampart CLO 2006-I Ltd.
  • T2 Income Fund CLO I Ltd
  • MORE

Standard & Poor's Ratings Services publishes monthly updates of the transaction-specific tranche recoveries we estimate for certain collateralized loan obligation (CLO) transactions included in our U.S. Corporate CDO EOD Index. For June 2011, we are providing the recovery values we estimated for 77 U.S. CLOs originated between 2003 and 2008 using our CLO tranche recovery metrics (TRM) framework (see table 1). We report the expected recovery amount as a percent of the current outstanding balance of each CLO tranche. A TRM of less than 100% indicates our view that the tranche might not receive full repayment under a given scenario. Standard & Poor's CLO TRMs are not ratings. Rather, they reflect a cash-flow-based recovery analysis for individual CLO tranches given...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown

- Southfork CLO Ltd.
- Castle Garden Funding
- BlueMountain CLO Ltd.
- Latitude CLO I Ltd
- Liberty CLO Ltd
- FM Leveraged Capital Fund I
- Trimaran CLO V Ltd
- 1776 CLO I Ltd
- AIMCO CLO, Series 2006-A
- Emporia Preferred Funding II Ltd
- Atrium V
- Latitude CLO II Ltd
- LightPoint CLO V Ltd
- Kingsland III Ltd.
- Stone Tower CLO V Ltd
- Rampart CLO 2006-I Ltd.
- HarbourView CLO 2006-1
- FM Leveraged Capital Fund II
- Ocean Trails CLO I
- Burr Ridge CLO Plus Ltd
- Bacchus (U.S.) 2006-1 Ltd
- Westbrook CLO Ltd.
- WhiteHorse IV Ltd
- Stone Tower CLO VI Ltd
- Foothill CLO I Ltd
- Golden Knight II CLO Ltd
- Emporia Preferred Funding III Ltd
- GSC Group CDO Fund VIII Limited
- Symphony CLO III Ltd
- Limerock CLO I
- Latitude CLO III Ltd.
- LightPoint CLO VII, Ltd.
- JMP Credit Advisors CLO I Ltd.
- Phoenix CLO III, Ltd
- Apidos Cinco CDO
- Telos CLO 2007-2 Ltd
- Voya CLO IV, Ltd.
- Canaras Summit CLO Ltd
- Ocean Trails CLO II
- Fore CLO Ltd 2007-1
- Primus CLO II Ltd
- Churchill Financial Cayman Ltd.
- Battalion CLO 2007-1, Ltd.
- T2 Income Fund CLO I Ltd
- Goldman Sachs Asset Management CLO PLC
- Halcyon Structured Asset Management Long Secured/Short Unsecured 2007-1 Ltd.
- Waterfront CLO 2007-1 Ltd
- Stone Tower CLO VII Ltd
- Flatiron CLO 2007-1 Ltd.
- Voya CLO V, Ltd.
- Ares XI CLO Ltd.
- Symphony CLO IV Ltd
- Muir Grove CLO Ltd
- Stratford CLO Ltd.
- Dryden XVIII Leveraged Loan 2007 Limited
- Gateway CLO Ltd.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.